Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SKYEY - SkyePharma PLC -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (13)	4/6/1999 2:37:00 PM
From: sim1	Respond to of 56

Thanks. US number 1-800-475-6701 for the replay works better. <eom>

To: Dr. John M. de Castro who wrote (13)	4/6/1999 6:21:00 PM
From: Rudy Saucillo	Read Replies (2) \| Respond to of 56

Very good conference call conducted by Michael Ashton/SkyePharma CEO and John Longenecker/formerly Depotech President. I recommend listening to the replay. In a nutshell... SkyePharma is actively looking for additional, similar acquisitions. That is, they're looking for companies which expand their drug delivery technology base and which have a product near to market. SkyePharma anticipates $50M/year in sales of DepoCyt as a treatment for lymphomatous meningitis in the 3-4 year timeframe as marketed by Chiron. SkyePharma expects to file DepoCyt in Europe (for neoplastic meningitis) in late summer. Approval is anticipated 12 months later. 2 Phase II studies of DepoMorphine in hip replacement surgery are expected to provide the data needed for a new partnership (and the 2nd contingent payment). Ashton anticipates a partnership in 3Q'99. The Phase IV studies required by the FDA accelerated approval guidelines include both solid tumor and lymphoma patients. These trials will take 3-4 years to complete. Rudy